Pharma major Lupin Limited (Lupin) announced the launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g pump act uation), having received an approval from the United States Food and Drug Administration (FDA).
Lupin's Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
- Primary hypogonadism (congenital or acquired) and
- Hypogonadotropic hypogonadism (congenital or acquired)
Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had an annual sales of approximately USD 893 million in t he US (IQVIA MAT December 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.810 as compared to the previous close of Rs. 803.95. The total number of shares traded during the day was 59878 in over 1340 trades.
The stock hit an intraday high of Rs. 812 and intraday low of 803.25. The net turnover during the day was Rs. 48367000.